Our Viewpoints

December 2021

Lessons From Evolution: From Innate Immunity to Novel Cancer Immunotherapies

In recent years, we’ve seen remarkable progress in combatting devastating cancers, with the rise of immunotherapies across a breadth of therapeutic modalities, from antibody-based immunomodulators to cell-based therapies to other emerging technologies. And yet, while there are more than 30 approved immunotherapies on the market today, only about 15-20% of patients respond to available treatments, demonstrating a necessity for more effective and tolerable options.

Advancing the Future of Oncology Through Precision Medicine

Over the past two decades, advancements in the industry have shifted how we diagnose, classify and ultimately treat certain cancers according to an individual’s molecular profile – a practice known as precision medicine. What does this transformative approach, and the diagnostics needed to achieve it, mean for the oncology industry, and most importantly, for patients with cancer? What gaps still remain, and how can stakeholders come together to address them?

November 2021

Takeda Demonstrates Progress in Advancing Health Economics at ISPOR 2021

Health economics (HE) analyzes the costs and consequences of healthcare interventions to evaluate their effects on patient-related clinical, humanistic, and economic outcomes.
At Takeda, we are committed to advancing the principles and practice of HE by collaborating with strategic partners to identify innovative and bold solutions that help ensure patients have access to our medicines.

We’re Back! Reflections on Returning to the Office

After over a year and a half of working from home, I looked forward to returning to the office as part of our new hybrid working environment. I’m a people person, and I really missed the energy that comes when working with colleagues face to face.

Building the Field Force of the Future

Today’s oncology field force in the pharmaceutical industry—the people  responsible for connecting patient care teams with therapeutic innovations—looks much different than it has in recent years.

September 2021

Why Leaders Should “Bless the Mess”

I am proud of how Takeda – like so many companies around the world – has adapted and embraced new ways of working over the past year-and-a-half. As Head of Global Oncology Patient Value, Policy and Access (PVPA) at Takeda, I also miss in-person interactions with my team and colleagues and look forward to returning to the workplace soon

August 2021

The Importance of Time Off from Work

I’ve always been a firm believer in the power of personal time off. I recently went on vacation and returned feeling completely revitalized. I find that this personal time away gives me a fresh perspective, renewed energy and space to think more creatively.

July 2021

Real-world evidence in the multiple myeloma treatment landscape

In our time at Takeda Oncology, we’ve had the opportunity to observe how real-world evidence (RWE) obtained outside of randomized controlled trials (RCTs) has been playing an increasingly important role in understanding treatment options for patients, especially in the field of multiple myeloma research.

Explore More

Leadership Team

Our Executive Leadership team is designed to drive customer proximity, nimbleness, agility and accountability 

R&D Approach

Decades of leadership in Oncology with a diverse and robust pipeline

Oncology Pipeline

Discovering and developing innovative therapies to deliver potentially transformative treatments